Search PubMed⌕ Search

Biomedical subjects

S M Wolf

Publications and source records attributed to S M Wolf.

At least 55 records · Page 3Linked to original sources
PubMed1978

Treatment of Bell palsy with prednisone: a prospective, randomized study.

Two hundred thirty-nine patients with Bell palsy were randomly distributed into prednisone-treated and control groups. Patients were followed until complete recovery or for 1 year. In the steroid-treated and control groups, respectively, incomplete recovery of facial strength occurred in 12 percent and 20 percent; motor synkinesis in 9 percent and 15 percent; autonomic synkinesis in 1 percent and 10 percent; and electromyographic evidence of severe denervation in 9 percent and 17 percent. The differences reached statistical significance only for autonomic synkinesis. In the total series recovery of facial strength was incomplete in 16 percent. Residual weakness was mild in 14 percent and moderate in 2 percent. No patient remained with severe weakness. Age, hyperacusis, and severity of the initial palsy were associated with an increased risk of poor outcome.

Adolescent↗
PubMed1978

Behavior disturbance, phenobarbital, and febrile seizures.

Of 109 children treated daily with phenobarbital following the first fibrile convulsion, 42% developed a behavior disorder, usually hyperactivity. Daily phenobarbital therapy was prematurely discontinued in 54% of the children with behavior abnormality (20% of those treated). The behavior disturbance usually appeared within several months, was no correlated with high blood barbiturate levels, disappeared in 73%, and improved in all children when barbiturate therapy was discontinued. No characteristics of the child, the initial febrile seizure, or recurrence of febrile seizures were significantly correlated with the occurrence of the behavior disorder except for behavioral abnormality preceding the initial febrile convulsion. Eighteen percent of the children who received no phenobarbital developed behavior disorder, most often hyperactivity. The behavior disturbance spontaneously disappeared in 52%. Among these children not given phenobarbital, the group with normal behavior had a greater frequency of family history of seizures, especially febrile convulsions, and a lower frequency of preseizure behavior disturbance; abnormalities of pregnancy, labor, delivery, and neonatal period; delayed milestones; long seizures; abnormal results of neurological examination; abnormal EEG; and recurrent febrile seizures.

Barbiturates↗
PubMed1977

Effect of ribavirin on Type 2 Herpesvirus hominis (HVH/2) in vitro and in vivo.

Ribavirin was found to inhibit five strains of HVH/2 tested in KB cells with the M1C range being 10-100 microgram/ml. In a mouse tail animal model, it effectively reduced HVH/2-induced lesions particularly at the peak lesion periods. Ribavirin was remarkably effective when intravaginal treatment was initiated late in the infection, which suggests that it may have potential for treatment of human cutaneous infections.

Animals↗
PubMed1977

Effectiveness of daily phenobarbital in the prevention of febrile seizure recurrences in "simple" febrile convulsions and "epilepsy triggered by fever".

Of 290 children with an initial febrile convulsion, 216 met Livingston's criteria for a "simple" febrile convulsion and 74 for "epilepsy triggered by fever." Daily phenobarbital produced a significant decrease in febrile seizure recurrences in both groups, as compared to children who received phenobarbital at the onset of fever and those who received no phenobarbital prophylaxis. Although statistically significant in both groups, the effectiveness of daily phenobarbital was more pronounced in the "epilepsy with fever" children.

Child↗
PubMed1977

The effectiveness of phenobarbital in the prevention of recurrent febrile convulsions in children with and without a history of pre-, peri- and postnatal abnormalities.

Three hundred children who had an initial febrile convulsion were divided into two groups. In one group were children with a single brief generalized initial febrile seizure and no history of pre-, peri- or postnatal abnormalities which might suggest the possibility of brain damage and in the other group those with such abnormalities and/or a "severe" initial febrile convulsion. Daily phenobarbital produced a significant decrease in febrile seizure recurrences in both groups, as compared to children who received phenobarbital at the onset of fever and no phenobarbital prophylaxis. "Intermitten" phenobarbital given at the onset of fever did not produce a significant difference in recurrence rate as compared with no phenobarbital.

Child↗
PubMed1977

The value of phenobarbital in the child who has had a single febrile seizure: a controlled prospective study.

A group of 355 children who were seen after a first febrile convulsion at the Kaiser Foundation Foundation Hospitals in Southern California from 1970 to 1975 were randomly assigned to three treatment groups-daily phenobarbital, "intermittent" phenobarbital given at the onset of fever, and no phenobarbital. We found that 42% had a relative with a febrile seizure and 16% a relative with an afebrile convulsion. 13% had seizures which were either lateralized or longer than ten minutes. Parents were unaware of the fever prior to the seizure in about 30% of the cases. In 81% the preseizure duration of fever was less than 24 hours. The mean follow-up was 28 months, with a range of 6 to 70 months. There was no significant difference in the recurrence rate between children receiving "intermitent" as compared with no phenobarbital. The recurrence rate in children receiving daily phenobarbital was significantly decreased compared to either of the other two groups. Severe recurrent febrile seizures occurred in no children on daily phenobarbital and in 4.4% of the children receiving either intermittent or no phenobarbital. Parental resistance, compliance, and reversible hyperactivity were the main problems encountered with the continuous phenobarbital regimen.

Child, Preschool↗
PubMed1976

Effect of 9-beta-D-arabinofuranosylhypoxanthine 5'-monophosphate on genital lesions and encephalitis induced by Herpesvirus hominis type 2 in female mice.

9-beta-D-Arabinofuranosylhypoxanthine 5'-monophosphate, administered orally or topically, increased the number of survivors and mean day of death in mice inoculated intravaginally with Herpesvirus hominis type 2. Topical application of the drug in ointment significantly reduced the severity of genital lesions. Orally administered drug did not appreciably reduce genital lesions, but it did cause significant increases in the number of survivors and mean day of death, even when administration was started as late as three days after inoculation of virus. Drug applied both topically and orally was more effective than drug applied by either route along. For topical application an ointment was found to be a better vehicle than polyvinyl alcohol or dimethysulfoxide. In some circumstances the vehicle of drug administration itself had some efficacy.

Administration, Oral↗
PubMed1975

Myelopathy simulating spinal cord tumor.

Three cases of demyelinating or necrotizing myelopathy are presented in which gradual onset of symptoms, slowly progressive course and widened cord shadow on myelography led to the erroneous diagnosis of intramedullary spinal cord neoplasm. Two of the cases also had inconclusive surgical explorations. We would suggest that patients who seem to have even a typical clinical and myelographic picutre of an intrinsic cord neoplasm have a period of further observation before radiotherapy is begun and that a vigorous search be made for evidence of disseminated disease.

Adult↗